Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA)

Titration of treatment dose to serum and urine MMA

Mark I. Evans, Debra A. Duguette, Piero Rinaldo, Erawati Bawle, David S. Rosenblatt, Janice Whitty, Ruben A. Quintero, Mark P. Johnson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective. Prenatally diagnosed methylmalonic aciduria (MMA) has been treated in only a few fetuses, and has been done empirically with maternally administered cyanocobalamin (B12) in attempts to ameliorate sequelae that include failure to thrive, developmental delay, dehydration, and coma. There has not been a systematic attempt to titrate doses to fetal response. We investigated the alterations in maternal dosage necessary to keep maternal plasma (MP) and urine (MU) levels of MMA in the normal range secondary to the ability of pharmacological doses of B12 to catalyze the reaction of methylmalonyl-coenzyme A to succinyl-coenzyme A. Methods. A 28-year-old woman, with a 3-year-old son affected with MMA, underwent amniocentesis at 15 weeks which showed a normal karyotype, elevated amniotic fluid MMA, and decreased amniocyte 5'-deoxyadenosylcobalamin, propionate, and methyltetrahydrofolate. MP and MU MMA levels were measured biweekly. B12 doses were altered periodically according to laboratory-determine levels. Results. MP and MU levels varied with gestational age and in response to increases in maternally administered B12 Conclusions. With increasing gestation, fetal, and placental size, increasing doses of B12 are necessary to maintain MP and MU levels of MMA within normal range. The data suggest that close surveillance and frequent measurements of MMA are necessary to properly titrate B12 treatment.

Original languageEnglish
Pages (from-to)21-23
Number of pages3
JournalFetal Diagnosis and Therapy
Volume12
Issue number1
StatePublished - Jan 1 1997

Fingerprint

Urine
Mothers
Serum
Therapeutics
Reference Values
Failure to Thrive
Aptitude
Amniocentesis
Propionates
Amniotic Fluid
Vitamin B 12
Coma
Methylmalonic acidemia
Nuclear Family
Karyotype
Dehydration
Gestational Age
Fetus
Pharmacology
Pregnancy

Keywords

  • Fetal therapy
  • Methylmalonic aciduria
  • Prenatal diagnosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Evans, M. I., Duguette, D. A., Rinaldo, P., Bawle, E., Rosenblatt, D. S., Whitty, J., ... Johnson, M. P. (1997). Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA): Titration of treatment dose to serum and urine MMA. Fetal Diagnosis and Therapy, 12(1), 21-23.

Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA) : Titration of treatment dose to serum and urine MMA. / Evans, Mark I.; Duguette, Debra A.; Rinaldo, Piero; Bawle, Erawati; Rosenblatt, David S.; Whitty, Janice; Quintero, Ruben A.; Johnson, Mark P.

In: Fetal Diagnosis and Therapy, Vol. 12, No. 1, 01.01.1997, p. 21-23.

Research output: Contribution to journalArticle

Evans, MI, Duguette, DA, Rinaldo, P, Bawle, E, Rosenblatt, DS, Whitty, J, Quintero, RA & Johnson, MP 1997, 'Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA): Titration of treatment dose to serum and urine MMA', Fetal Diagnosis and Therapy, vol. 12, no. 1, pp. 21-23.
Evans, Mark I. ; Duguette, Debra A. ; Rinaldo, Piero ; Bawle, Erawati ; Rosenblatt, David S. ; Whitty, Janice ; Quintero, Ruben A. ; Johnson, Mark P. / Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA) : Titration of treatment dose to serum and urine MMA. In: Fetal Diagnosis and Therapy. 1997 ; Vol. 12, No. 1. pp. 21-23.
@article{91ba99fd1c6747598b9334ccdd08129d,
title = "Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA): Titration of treatment dose to serum and urine MMA",
abstract = "Objective. Prenatally diagnosed methylmalonic aciduria (MMA) has been treated in only a few fetuses, and has been done empirically with maternally administered cyanocobalamin (B12) in attempts to ameliorate sequelae that include failure to thrive, developmental delay, dehydration, and coma. There has not been a systematic attempt to titrate doses to fetal response. We investigated the alterations in maternal dosage necessary to keep maternal plasma (MP) and urine (MU) levels of MMA in the normal range secondary to the ability of pharmacological doses of B12 to catalyze the reaction of methylmalonyl-coenzyme A to succinyl-coenzyme A. Methods. A 28-year-old woman, with a 3-year-old son affected with MMA, underwent amniocentesis at 15 weeks which showed a normal karyotype, elevated amniotic fluid MMA, and decreased amniocyte 5'-deoxyadenosylcobalamin, propionate, and methyltetrahydrofolate. MP and MU MMA levels were measured biweekly. B12 doses were altered periodically according to laboratory-determine levels. Results. MP and MU levels varied with gestational age and in response to increases in maternally administered B12 Conclusions. With increasing gestation, fetal, and placental size, increasing doses of B12 are necessary to maintain MP and MU levels of MMA within normal range. The data suggest that close surveillance and frequent measurements of MMA are necessary to properly titrate B12 treatment.",
keywords = "Fetal therapy, Methylmalonic aciduria, Prenatal diagnosis",
author = "Evans, {Mark I.} and Duguette, {Debra A.} and Piero Rinaldo and Erawati Bawle and Rosenblatt, {David S.} and Janice Whitty and Quintero, {Ruben A.} and Johnson, {Mark P.}",
year = "1997",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "21--23",
journal = "Fetal Diagnosis and Therapy",
issn = "1015-3837",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA)

T2 - Titration of treatment dose to serum and urine MMA

AU - Evans, Mark I.

AU - Duguette, Debra A.

AU - Rinaldo, Piero

AU - Bawle, Erawati

AU - Rosenblatt, David S.

AU - Whitty, Janice

AU - Quintero, Ruben A.

AU - Johnson, Mark P.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Objective. Prenatally diagnosed methylmalonic aciduria (MMA) has been treated in only a few fetuses, and has been done empirically with maternally administered cyanocobalamin (B12) in attempts to ameliorate sequelae that include failure to thrive, developmental delay, dehydration, and coma. There has not been a systematic attempt to titrate doses to fetal response. We investigated the alterations in maternal dosage necessary to keep maternal plasma (MP) and urine (MU) levels of MMA in the normal range secondary to the ability of pharmacological doses of B12 to catalyze the reaction of methylmalonyl-coenzyme A to succinyl-coenzyme A. Methods. A 28-year-old woman, with a 3-year-old son affected with MMA, underwent amniocentesis at 15 weeks which showed a normal karyotype, elevated amniotic fluid MMA, and decreased amniocyte 5'-deoxyadenosylcobalamin, propionate, and methyltetrahydrofolate. MP and MU MMA levels were measured biweekly. B12 doses were altered periodically according to laboratory-determine levels. Results. MP and MU levels varied with gestational age and in response to increases in maternally administered B12 Conclusions. With increasing gestation, fetal, and placental size, increasing doses of B12 are necessary to maintain MP and MU levels of MMA within normal range. The data suggest that close surveillance and frequent measurements of MMA are necessary to properly titrate B12 treatment.

AB - Objective. Prenatally diagnosed methylmalonic aciduria (MMA) has been treated in only a few fetuses, and has been done empirically with maternally administered cyanocobalamin (B12) in attempts to ameliorate sequelae that include failure to thrive, developmental delay, dehydration, and coma. There has not been a systematic attempt to titrate doses to fetal response. We investigated the alterations in maternal dosage necessary to keep maternal plasma (MP) and urine (MU) levels of MMA in the normal range secondary to the ability of pharmacological doses of B12 to catalyze the reaction of methylmalonyl-coenzyme A to succinyl-coenzyme A. Methods. A 28-year-old woman, with a 3-year-old son affected with MMA, underwent amniocentesis at 15 weeks which showed a normal karyotype, elevated amniotic fluid MMA, and decreased amniocyte 5'-deoxyadenosylcobalamin, propionate, and methyltetrahydrofolate. MP and MU MMA levels were measured biweekly. B12 doses were altered periodically according to laboratory-determine levels. Results. MP and MU levels varied with gestational age and in response to increases in maternally administered B12 Conclusions. With increasing gestation, fetal, and placental size, increasing doses of B12 are necessary to maintain MP and MU levels of MMA within normal range. The data suggest that close surveillance and frequent measurements of MMA are necessary to properly titrate B12 treatment.

KW - Fetal therapy

KW - Methylmalonic aciduria

KW - Prenatal diagnosis

UR - http://www.scopus.com/inward/record.url?scp=0030610123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030610123&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 21

EP - 23

JO - Fetal Diagnosis and Therapy

JF - Fetal Diagnosis and Therapy

SN - 1015-3837

IS - 1

ER -